试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-08
Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis
编号:NCT04826432登记状态:提前终止企业 / 申办者:Gustave Roussy, Cancer Campus, Grand Paris
药物 / 成分:Pasireotide 0.9 MG/ML、Saline water
登记的停止原因(原文):No more experimental drugs available
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-08
Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia
编号:NCT05116046登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Recifercept
登记的停止原因(原文):The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-08
A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.
编号:NCT05644600登记状态:提前终止企业 / 申办者:AstraZeneca
药物 / 成分:Nintedanib、AZD5055
登记的停止原因(原文):The study was terminated as no drug-drug interactions were observed in Part-A of the study and therefore Part-B of the study was not required as per protocol.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
编号:NCT02545127登记状态:提前终止企业 / 申办者:Ferring Pharmaceuticals
药物 / 成分:Merotocin、Placebo
登记的停止原因(原文):The trial was prematurely terminated. Termination was not because of safety concerns but due to slow recruitment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
编号:NCT03393858登记状态:提前终止企业 / 申办者:Capital Medical University
药物 / 成分:Anti-PD-1 antibody、DC-CIK Immunotherapy、Thermotron RF-8EX
登记的停止原因(原文):The number of enrolled cases is insufficient
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
编号:NCT03834220登记状态:提前终止企业 / 申办者:Debiopharm International SA
药物 / 成分:Debio 1347
登记的停止原因(原文):Due to lower antitumor activity than expected
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
编号:NCT04071756登记状态:提前终止企业 / 申办者:Dana-Farber Cancer Institute
药物 / 成分:Topical Tazarotene、Placebo
登记的停止原因(原文):Difficulty with patient recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
编号:NCT04333147登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:Otilimab (GSK3196165)、csDMARD(s)
登记的停止原因(原文):Study is early terminated due to Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
Leflunomide in Mild COVID-19 Patients
编号:NCT04361214登记状态:提前终止企业 / 申办者:University of Chicago
药物 / 成分:Leflunomide
登记的停止原因(原文):Terminated by PI
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-07
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning.
编号:NCT04386811登记状态:提前终止企业 / 申办者:Yale University
药物 / 成分:Calcitriol、Placebo
登记的停止原因(原文):Following Yale University resuming in-person research activities, the investigators no longer had dedicated funding for the study and were unable to secure additional funding to meet the research goals.
查看官方原始记录 ↗